ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 447

High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis

Claire I. Daien1,2, Sarah Gailhac3, Thibault Mura4, Bernard Combe2, Michael Hahne1 and Jacques Morel5, 1IGMM, CNRS UMR5535, Montpellier, Montpellier, France, 2Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 3Igmm UMR3555, CNRS, Montpellier, France, 4CIC, Hopital Gui De Chauliac, Montpellier, France, 5Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: anti-TNF therapy, B cell memory, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis.  We studied the effect of TNFi on peripheral B cells and elucidated B cell related biomarkers to predict TNFi response.

Methods: Peripheral B cells were analyzed for expression of CD19, CD27, CD38, IgD in 31 healthy donors and 96 RA patients, including 21 patients who were followed 3 months after TNFi introduction. We compared B cell subsets between patients with RA and controls; TNFi and non TNFi users as well as before and after TNFi introduction in RA patients. We also aimed to identify phenotypes associated with EULAR response.

Results: B cell subsets in blood were influenced by age and glucocorticoids doses. After adjustment on age, gender and glucocorticoid doses, patients with RA were found to have similar B cell subset frequencies as controls. No significant effect of TNFi on B cell repartition was found when comparing TNFi and non TNFi users at baseline or patients before and after TNFi introduction. TNFi responders at 3 months had significantly higher percentage of CD27+ memory B cells at baseline and those with CD27+ above 26% at inclusion were 4.9 (1.3-18.6) more likely to respond TNFi treatment. CD27+ cells produced 3 times more TNF alpha than naïve B cells which was correlated with IFN gamma-producing CD4+in patients free of TNFi.

Conclusion: High levels of memory B cells at baseline were associated with response to TNFi which may be related to the  activation of the Th1 pathway in a TNFa depending manner.


Disclosure:

C. I. Daien,
None;

S. Gailhac,
None;

T. Mura,
None;

B. Combe,
None;

M. Hahne,
None;

J. Morel,

Pfizer Inc,

2,

Bristol-Myers Squibb,,

5,

Abbott Laboratories,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Merck Pharmaceuticals,

5.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2013

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-levels-of-memory-b-cells-are-associated-with-response-to-a-first-anti-tnf-drug-in-patients-with-rheumatoid-arthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology